Moore Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Moore Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.17M	Hold	275,000	–	–	0.02%	465
2026 Q1	$1.28M	Hold	275,000	–	–	0.03%	343
2025 Q4	$1.95M	Buy	275,000 +150,000	+120%	+$1.11M	0.03%	390
2025 Q3	$968K	Buy	125,000 +50,000	+67%	+$377K	0.01%	433
2025 Q2	$521K	Buy	75,000 +25,000	+50%	+$199K	0.01%	420
2025 Q1	$425K	Buy	+50,000	New	+$589K	0.01%	368

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Moore Capital Management's BCYC Position: Q2 2026 in Review

Moore Capital Management held its Bicycle Therapeutics (BCYC) position steady in Q2 2026 at 275,000 shares worth $1.17M. The position accounts for 0.02% of the portfolio, ranked #465.

Moore Capital Management first reported a position in BCYC in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.95M in Q4 2025. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

Moore Capital Management held 275,000 shares of Bicycle Therapeutics worth $1.17M as of Q2 2026.
Moore Capital Management left its Bicycle Therapeutics share count unchanged in Q2 2026.
Bicycle Therapeutics made up 0.02% of Moore Capital Management's portfolio in Q2 2026, its #465 holding.
Moore Capital Management first reported a position in Bicycle Therapeutics in Q1 2025 and has held it in 6 quarters since.
Moore Capital Management's Bicycle Therapeutics position peaked at $1.95M in Q4 2025.
103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.